Arcutis Biotherapeutics Accounts Payable

Arcutis Biotherapeutics (ARQT) currently reports a accounts payable of $6.6M as of June 2026. That compares with $15M in the prior-year period — down 56.2% year over year. Use the charts on this page to explore Arcutis Biotherapeutics's accounts payable history and peer comparisons.

Arcutis Biotherapeutics's accounts payable decreased from $15M to $6.6M — a 56.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Arcutis Biotherapeutics reported $6.6M in accounts payable as of June 2026. That compares with $15M in the prior-year period — down 56.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $6.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Arcutis Biotherapeutics, and consider following ARQT for alerts when major investors trade the stock.

Arcutis Biotherapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $6.6M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ARQT with unrelated industries.